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Each year approximately 1.4 million people worldwide are
diagnosed with lung cancer – 12% of all new cases of cancer.
Small cell lung cancer (SCLC) now represents only 13% of all newly
diagnosed lung cancers. The SEER database indicates that the
annual incidence of SCLC has been decreasing over the past 30
years (Field and Duffy, 2008), More than 90% of patients with
SCLC are current or past smokers, and the risk is related to the
duration and intensity of the smoking (Brownson et al, 1992). The
median age at diagnosis in developed countries is approximately
68 years, and as many as 31% of patients may be aged 70 years or
older (Yau et al, 2006).
STAGING
The SCLC is an aggressive disease associated with early loco-
regional and distant metastases and paraneoplastic syndromes
(Lally et al, 2007). It has a different staging system to that of other
solid tumours (Chua et al, 2004). The Veterans Affairs Adminis-
tration Lung Cancer Study Group (VALG) two-stage classification
system introduced in 1957 the terms limited disease (LD) and
extensive disease (ED) (Felip et al, 2005). Thirty years later, the
consensus report of the International Association of Lung Cancer
(IASLC) modified the VALG classification (Stahel et al, 1989).
They recommended including patients with ‘ipsilateral and
contralateral, hilar, mediastinal and supraclavicular nodes’ as
LD. They also included patients with ipsilateral pleural effusion
regardless of the cytology in the limited subgroup.
A Japanese series reported the comparison of a group of patients
who received definitive thoracic radiotherapy (TRT) in which the
pleural effusion had disappeared after induction chemotherapy,
with a second group who did not receive TRT despite response and
a third group with a pleural effusion that did not respond to
chemotherapy. Long-term survival was achieved in those patients
who successfully underwent chemoradiotherapy (Niho et al, 2008).
An ongoing retrospective survival analysis of data from 48000
SCLC patients in the IASLC database, many of whom were treated
surgically, showed that survival of patients with LD and effusion is
intermediate between those of patients with LD without effusion
and patients with ED. The data suggest that clinical TNM staging
can identify subgroups of patients with distinct prognoses within
the conventional definition of LD and that all effusion should be
cytologically proven (Shepherd et al, 2007). Such findings have led
to the new recommendations for lung cancer staging based on the
AJCC/UICC TNM seventh edition that are likely to supersede the
VALG system in future clinical trials of SCLC (Detterbeck et al,
2009).
PROGNOSTIC FACTORS
Disease stage remains the most powerful prognostic factor for
SCLC. The Manchester scoring system is frequently used in the
clinic as an indicator of prognosis in SCLC. It is calculated from a
number of physical and biochemical markers, including serum
lactate dehydrogenase, serum sodium concentration, serum alka-
line phosphatase, serum bicarbonate, Karnofsky performance
status (PS) and stage of disease (Cerny et al, 1987). Prognosis
for patients with SCLC is poor, even in those with early stage (non-
metastatic) SCLC. From the time of diagnosis, the median ranges
of survival for LD-SCLC and ED-SCLC are 15–20 and 8–13
months, respectively. Approximately 20–40% of patients with LD-
SCLC and 5% of patients with ED-SCLC survive for 2 years (Lally
et al, 2007).
TREATMENT OF LIMITED STAGE
The survival of patients with LD-SCLC has improved over the past
20 years, with a 5-year survival rate of 13.9% compared with 6%
before 2000 in our own institution – the Royal Marsden Hospital
(Figure 1). The positive outcome in LD seems to be multifactorial,
with better staging, platinum-based chemotherapy and the use of
prophylactic cranial irradiation (PCI) all exerting an effect. The
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www.bjcancer.comaddition of TRT to chemotherapy, both sequentially and, more
recently, concomitantly, significantly reduces the risk of intrathor-
acic failures, resulting in improvements in long-term survival in
this population (Pignon et al, 1992).
Surgery
The function of surgery has never been fully developed because of
the apparent failure of this treatment modality in two randomised
trials reported in 1976 and 1994. Both trials did not show any
survival advantage for surgery alone or in combination with TRT,
compared with radiotherapy alone (Fox and Scadding, 1973; Lad
et al, 1994). A recent review of these data suggests that the
‘intention to treat’ results may have misrepresented the effect of
surgery, as not all patients randomised to surgery and included in
the analyses actually underwent a complete resection. In fact, only
48% and 77% of patients, respectively, did so, meaning that the
impact of surgery may have been underestimated.
A more recent retrospective analysis of surgery for patients with
stage I–IIIB at the Royal Brompton Hospital reported a 5-year
progression-free survival (PFS) of 46% (Lim and Goldstraw, 2008).
Other published prospective series also suggest that surgery, after
induction chemotherapy, can achieve high local control rates in
early stage SCLC (stage I–III) with favourable long-term survival
results (Fujimori et al, 1997; Eberhardt et al, 1999). The survival
rates reported are higher than the historical control, with 63% and
46% of patients alive at 3 and 5 years, respectively. To validate this
hypothesis, a number of randomised trials have recently been
designed to compare surgery, in combination with chemotherapy
or chemoradiotherapy, with the current standard of treatment with
chemoradiotherapy using modern staging methods.
Chemoradiation
Combined modality therapy with chemotherapy and thoracic
irradiation is the current accepted standard for patients with LD-
SCLC (NCCN, 2008). Two meta-analyses have established the
function of TRT in the management of patients with LD (Pignon
et al, 1992; Warde and Payne, 1992). Both reports found an
improved intrathoracic tumour control rate with combined
modality patients and statistically improved survival with an
absolute benefit in overall survival (OS) at 3 years (Pignon et al,
1992) and 2 years (Warde and Payne, 1992) of 5.4%. Treatment-
related toxicity is worse with combination treatments, but is
acceptable in patients with a good PS.
There are a number of unresolved issues in the delivery of
chemotherapy and radical radiotherapy in LD-SCLC including
timing of TRT, early vs late, concomitant or sequential, total dose
and fractionation schedule. Many trials have addressed the timing
issues, but they have differed in trial design as well as the
chemotherapy regimen used as reviewed recently by Socinski and
Stinchcombe (2007).
A number of meta-analyses have shown a modest survival
benefit with early compared with delayed concurrent TRT, most
notably in combination with a cisplatin-based regimen (Fried et al,
2004; Huncharek and McGarry, 2004; Socinski and Stinchcombe,
2007). Additional analyses indicate that the overall treatment time
for TRT, as well as the time of TRT initiation, influences survival.
A Cochrane review of seven trials observed a significant survival
benefit at 5 years for patients who had early radiotherapy delivered
within an overall treatment time of 30 days (Pijls-Johannesma
et al, 2005). A second analysis found that patients who received
their last dose of TRT o30 days after the first dose of
chemotherapy had a significantly greater likelihood of survival at
5 years compared with completion of TRT 430 days after
chemotherapy initiation (De Ruysscher et al, 2006).
A landmark study by Turrisi et al (1999) showed that a
hyperfractionation regimen of 45Gy given twice daily over a 3-
week period was associated with significantly improved OS at 5
years compared with 45Gy once daily over 5 weeks (26% vs 16%;
P¼0.04). Tolerability was comparable between the groups,
although osophagitis was reported significantly more frequently
in the twice-daily dosing group. Relapse rates in patients given
once-daily TRT were significantly higher leading to the suggestion
that patients in this arm were under-dosed. A trial has recently
commenced comparing 45Gy twice daily in 1.5Gy fractions vs
66Gy once daily in 2Gy fractions that should provide further
guidance on optimisation and standardisation of radiotherapy for
LD-SCLC (Faivre-Finn and Falk, 2009).
It should be noted that EP remains the only chemotherapy that
can be delivered at full dose in combination with radiotherapy in
LD-SCLC.
TREATMENT OF ED
Chemotherapy is the main treatment for ED-SCLC. Treatments in
the past including oral etoposide, standard- and high-dose
regimens have been extensively reviewed by the authors in an
earlier publication (Popat and O’Brien, 2005). Combination
therapy with EP is considered the standard first-line regimen
(Sundstrom et al, 2002), but a randomised Phase III trial failed to
prove a definitive survival benefit for EP compared with the
cyclophosphamide, doxorubicin and vincristine regimen (CAV)
(Roth et al, 1992). In a recent trial (Sundstrom et al, 2002), a
significant survival advantage in favour of the EP arm was seen for
LD patients, but only a trend in survival benefit was seen in the ED
group, with a median survival of 8.4 months as compared with 6.5
months in the CAV arm (P¼0.21). The recently published
Cochrane review in SCLC concluded that there was no statistical
survival benefit from platinum-based regimens. There was an
improvement in complete response rates, which is important in
LD; however, there was greater toxicity in terms of emesis,
anaemia and thrombocytopaenia. LD-SCLC and ED-SCLC were not
separated. The review highlights the lack of quality-of-life (QoL)
data. Major differences in QoL between an anthracycline and
platinum-based regimen are not expected with modern powerful
anti-emetics, and the haematological toxicities of anaemia and
thrombocytopaenia can be managed (Amarasena et al, 2008). It is
unlikely that a head-to-head study will be repeated with QoL
assessment at this point in time.
A randomised Phase III study of EP vs carboplatin and
etoposide (CE) showed no differences in response and survival
between the two treatment arms, although the study was not
powered for non-inferiority (Skarlos et al, 1994). A more recent
randomised trial comparing split doses of EP vs CE in elderly or
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Figure 1 Survival rates of patients with LD-SCLC pre-2000: 5-year
survival 13.9% vs 6.1%; 2-year survival 17% vs 27%. (Unpublished data from
the Royal Marsden Hospital, UK.)
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significant difference in response rate or survival (Okamoto
et al, 2007). Given these data, several cytotoxic drugs identified
as active against SCLC have been tested in combination with
cisplatin or carboplatin (Table 1).
A study conducted by the Japan Clinical Oncology Group
showed a significant survival benefit for irinotecan and cisplatin
combination vs EP (Noda et al, 2002), but a second study in US
patients of the same agents failed to show any significant
difference (Hanna et al, 2006a). A recent pharmacogenomic
analysis of Japanese and US patients treated with carboplatin
and paclitaxel for non-SCLC revealed that differences in outcomes
for survival and toxicity could be explained by genotypic
variations between the two nationalities (Gandara et al, 2009).
The investigators found significant differences between Japanese
and US patients in the frequency of variant alleles for genes
encoding enzymes involved in paclitaxel metabolism and DNA
repair. Exploratory analyses revealed significant associations
between some of these variant alleles and patients’ treatment
response and survival. A similar genetic basis may explain the
different responses to irinotecan and cisplatin in SCLC. Indeed, it
is established that the variety in allelic distribution of enzymes
involved in irinotecan metabolism differ between Japanese and
Caucasian patients (Ando et al, 2002).
Topotecan has shown significant anti-tumour activity and
symptom palliation in relapsed SCLC. The doublet oral topotecan
plus cisplatin (TC) showed both similar benefit and toxicity to EP.
Grades 3 and 4 neutropaenia were more frequent with EP (84% vs
59%), whereas TC caused a higher rate of anaemia (38% vs 21%),
thrombocytopaenia (38% vs 23%) and diarrhoea (33% vs 18%), but
a lower rate of alopecia (TC 24% vs PE 40%) (Eckardt et al, 2006;
Heigener et al, 2008).
Two Phase III randomised studies have investigated the possible
function of paclitaxel in SCLC by adding paclitaxel to the
platinum/etoposide doublet. Both trials led to similar conclusions
and failed to show a benefit in survival for the experimental arm,
but reported an increase in haematological and non-haematolo-
gical toxicity, and a higher rate of toxicity-related death
(Mavroudis et al, 2001; Niell et al, 2005).
A Phase III trial, evaluating pemetrexed and carboplatin, which
was closed after a planned interim analysis showed inferior PFS in
the experimental arm compared with the standard etoposide and
platinum combination (Socinski et al, 2009).
A non-inferiority trial was designed to determine whether
gemcitabine plus carboplatin (GC) would be less toxic, and
associated with better QoL when compared with EP chemotherapy.
The GC chemotherapy achieved survival rate, response rate and
time to progression equivalent to EP. The two regimens had a
different toxicity profile; a higher rate of grades 2–3 nausea and
alopecia occurred in EP-treated patients, whereas more frequent
grades 3 and 4 haematological toxicity were seen with the GC
schedule (Lee et al, 2009). A more realistic comparison would have
been GC and CE, and a comparative study of these combinations
would be of interest. The GC regimen is useful, particularly in
patients with mixed small cell and non-small cell tumours, and for
those for whom alopecia is a real problem.
To summarise these results, all the recent randomised trials
using later generation cytotoxics have not had a significant impact
on standard care for SCLC, failing to identify a new platinum-
based combination over the established platinum etoposide.
NEW AGENTS AND ONGOING RESEARCH
Amrubicin is a synthetic anthracycline and a potent topoisomerase
II inhibitor approved in Japan for the treatment of SCLC. As a
first-line therapy for ED, amrubicin in combination with cisplatin
achieved an impressive response rate of 88% and a median OS of
13.6 months in Japan (Ohe et al, 2005). Clinical trials are ongoing
in the United States and Europe to determine whether amrubicin
will be effective in other ethnic groups.
Targeted agents are also an area of considerable interest given
their success in other tumour types. The SCLC has been identified
as a highly angiogenic tumour and a number of pro-angiogenic
circulating factors have been implicated in this disease. Thalido-
mide has anti-angiogenic properties and has been investigated
earlier in combination with first-line chemotherapy and as
maintenance therapy in Phase II trials (Dowlati et al, 2007;
Table 1 Phase II/III studies of combination chemotherapy in patients with ED-SCLC
Experimental regimen
Standard regimen
Outcomes
Author Staging Patients (n) Schedule Schedule Overall survival (months) RR
Noda et al (2002) ED 154 Irinotecan/
cisplatin
I: 60mg/m
–2days 1, 8, 15
P: 60mgm
–2day 1; q4w
E: 100mgm
–2days 1, 2, 3
P: 80mgm
–2day 1; q3w
12.8 vs 9.4 months +ve +ve
Hanna et al (2006a) ED 331 I: 65mgm
–2days 1, 8
P: 30mgm
–2days 1, 8; q3w
E: 120mgm
–2days 1,2,3
P: 60mgm
–2day 1; q3w
9.3 vs 10.2 months NS NS
Lara et al (2009) ED 645 I: 60mgm
–2days 1, 8, 15
P: 60mgm
–2day 1; q4w
E: 100mgm
–2days 1,2,3
P: 80mgm
–2day 1; q3w
9.9 vs 9.1 months NS NS
Hermes et al (2008) ED 220 Irinotecan/
carboplatin
I: 175mgm
–2day 1
Ca: AUC 4 day 1; q3w
E: 120mgm
–2orally days 1–5
Ca: AUC 4 day 1; q3w
8.5 vs 7.1 months +ve /
Socinski et al (2009) ED 733 Pemetrexed/
carboplatin
Pe: 500mgm
–2day 1
Ca: AUC 5 day 1; q3w
E: 100mgm
–2days 1, 2, 3
Ca: AUC 5 day 1; q3w
7.29 vs 9.56 months –ve –ve
Niell et al (2005) ED 587 Paclitaxel/
etoposide/
cisplatin
Pa: 175mgm
–2day 1
E: 80mgm
–2days 1–3
P: 80mgm
–2day 1; q3w
E: 80mgm
–2days 1, 2, 3
P: 80mgm
–2day 1; q3w
10.6 vs 9.9 months NS +ve
Mavroudis et al (2001) ED, LD 133 Pa: 175mgm
–2day 1
E: 80mgm
–2days 1–4
P: 80mgm
–2day 2; q3w
E: 120mgm
–2days 1, 2, 3
P: 80mgm
–2day 1; q3w
9.5 vs 10.5 months NS NS
Heigener et al (2008) ED 795 Topotecan/
cisplatin
T: 1mgm
–2days 1–5
P: 75mgm
–2day 1; q3w
E: 100mgm
–2days 1, 2, 3
P: 75mgm
–2day 1; q3w
10.3 vs 9.4 months Non-inferior +ve
Eckardt et al (2006) ED 784 T: 1.7mgm
–2oral days 1–5
P: 60mgm
–2day 5; q3w
E: 100mgm
–2days 1, 2, 3
P: 80mgm
–2day 1; q 3w
39.3 vs 40.3 weeks Non-inferior NS
Lee et al (2009) ED, LD, poor
prognoses
241 Gemcitabine/
carboplatin
G: 1200mgm
–2days 1, 8
Ca: AUC 5 day 1; q3w
E: 120mgm
–2day 1; 100mgm
–2
bd orally days 2, 3
P: 60mgm
–2day 1; q3w
8 vs 8.1 months Non-inferior NS
Abbreviations: P¼cisplatin; Ca¼carboplatin; E¼etoposide; I¼irinotecan; Pe¼pemetrexed; Pa¼paclitaxel; T¼topotecan; G¼gemcitabine; RR¼response rate; NS¼not
significant; AUC¼area under the curve; ED¼extensive disease; LD¼limited disease; SCLC¼small cell lung cancer.
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have failed to show any benefit for thalidomide plus chemotherapy
over chemotherapy alone (Pujol et al, 2007; Lee et al, 2009). In the
most recent studies, an analysis of data from over 700 patients
failed to show any difference in OS or PFS between the groups, but
did show a significant increase in the risk of thrombotic events
with thalidomide (Lee et al, 2009).
Maintenance therapy with vandetanib (ZD6474), a VEGF receptor
tyrosine kinase inhibitor, did not increase OS or PFS when
compared with placebo (Arnold et al, 2007). In addition,
bevacizumab in first-line treatment of SCLC – in combination with
either cisplatin and etoposide or cisplatin and irinotecan – has not
yielded results as promising as was expected (Ready et al, 2007;
Sandler et al, 2007); however, further results are awaited. Taken
together, these data suggest that targeting angiogenesis in SCLC with
current approaches may not work as well as in other tumour types.
Increased understanding of the molecular mechanism of tumour
resistance to apoptosis has led to the development of promising
targeted therapies, which selectively modulate pro- and anti-
apoptotic proteins. Small molecule inhibitors of bcl-2 family anti-
apoptotic members are currently under evaluation in Phase I and
II trials. The first Phase II trial with the bcl-2 anti-sense
oligonucleotide oblimersen as initial therapy for ED-SCLC has
been negative, suggesting worse outcome for patients receiving
oblimersen in association with CE, compared with CE alone. The
response rates were the same in both treatment arms (61% vs
60%), whereas the percentage of patients alive at 1 year was 24%
with oblimersen and 47% without oblimersen (Rudin et al, 2008).
To date, none of the new-targeted agents investigated have been
found to alter the clinical history of SCLC.
Prophylactic cranial irradiation
Approximately 14–24% of patients with SCLC have detectable
brain metastases (BM) at the time of initial diagnosis (Argiris and
Murren, 2001). Data regarding the efficacy of chemotherapy in
patients with brain relapse is scanty, although responses do occur
(Postmus et al, 1989, 1995; Groen et al, 1993). Survival after
metastasis to the brain is short, ranging from about 3 to 5 months
(Postmus et al, 1998, 2000).
Trials conducted in the late 1980s and early 1990s, and two
subsequent meta-analyses, have confirmed that PCI significantly
improves survival for patients with SCLC who achieved a complete
response (using chest X-rays) after induction treatment, with an
absolute improvement in OS of 5.4% at 3 years (Auperin et al,
1999; Prophylactic-Cranial-Irradiation-Overview-Collaborative-
Group, 2000). As revealed by a CT scan, PCI is also now offered
to patients with a good partial response.
The function of PCI in patients with ED-SCLC after chemotherapy
has recently been investigated in a randomised Phase III trial
conducted by the EORTC lung group (Slotman et al,2 0 0 7 ) .T h e
incidence of symptomatic BM, the primary objective of the trial, was
significantly reduced after PCI in patients who did not progress on
initial systemic therapy. The cumulative risk of metastases at 1 year
was 14.6% in the PCI arm compared with 40.4% in the control arm.
The median survival increased from 5.4 to 6.7 months after
randomisation, and the 1-year survival rate was 27.1% in the
irradiation group and 13.3% in the control group. However, it
should be noted that brain imaging was not conducted in this trial
before randomisation unless patients displayed symptoms indicative
of BM. Nevertheless, a recent UK survey reports quick implementa-
tion of PCI in patients with ED-SCLC in radiotherapy centres based
on the EORTC data (Bayman et al, 2008, 2009).
TREATMENT OPTIONS FOR RELAPSED SCLC
Despite high initial response rates to chemotherapy, SCLC usually
recurs within 1 year after treatment (Ardizzoni, 2004). It is
estimated that 80% of patients with LD, and almost all
patients with ED, relapse or experience disease progression (Clark
and Ihde, 1998). As the prognosis is poor, symptom palliation and
maintenance of QoL are important therapeutic goals in the
relapsed setting (Gralla, 2004; Nicum and O’Brien, 2007).
Chemotherapy options
On the basis of retrospective data, distinction has been made
between (1) sensitive patients, that is those with a response to first-
line therapy and a treatment-free interval of at least 90 days, (2)
resistant patients, that is relapse within 90 days and (3) refractory
patients, that is no response to first-line treatment (Vincent et al,
1988; Fischer and Arcaro, 2008). The PS and sensitivity to initial
chemotherapy were found to be prognostic and predictive
variables for chemotherapy outcome in recurrent SCLC patients
(Kim et al, 2008). The relevance of these categories has recently
been called into question with respect to re-treatment decisions
(O’Brien et al, 2006).
The CAV may be used after first-line treatment with EP, with a
response rate of 8–28% (von Pawel et al, 1999). A trial of the
Norwegian lung cancer study group has evaluated the benefit of
crossover chemotherapy with CAV at relapse after primary
treatment with EP, compared with EP at relapse after CAV.
There was no survival difference between the two crossover
treatment groups (median survival after relapse was 3.9 and 4.5
months, respectively), and no differences in outcomes were
observed in either resistant or sensitive patients. Nevertheless,
these data are from a selected subgroup of patients, because only a
limited number of patients (42%) from the initial-treated
population were considered to be suitable for second-line
chemotherapy at the time of disease progression. Moreover, a
comparison between the second-line chemotherapy and the best
supportive care group, in a non-randomised design, revealed a
significantly better survival rate in favour of the chemotherapy
group, although this difference could be explained by more
negative prognostic factors in the best supportive care group
(Sundstrom et al, 2005).
Single-agent topotecan is currently the only approved drug for
the treatment of patients with SCLC who have failed or relapsed
after first-line chemotherapy. Topotecan is available in both
intravenous and oral formulations and randomised studies
have suggested that both have similar clinical activity in SCLC
(von Pawel et al, 2001; Eckardt, 2003). A randomised Phase III trial
has shown significant benefit with oral topotecan plus best
supportive care vs best supportive care only in relapsed patients
unsuitable for intravenous regimens (Table 2). The OS was
significantly longer in the topotecan group (median survival
25.9 vs 13.9 weeks), and survival was preserved in patients with a
short time to progression after first-line therapy (60 days) and in
those with a PS score of 2. Moreover, patient QoL and symptom
control was significantly greater in patients who received
topotecan (O’Brien et al, 2006). A randomised trial comparing
intravenous topotecan with the CAV regimen observed compar-
able response rates (24.3% and 18.3%, respectively) and median
survival (25.0 and 24.7 weeks), although topotecan was associated
with greater symptom improvement in terms of improved
dyspnoea, anorexia, fatigue, insomnia and daily activity (von
Pawel et al, 1999).
Other evaluated drugs
Over the past years, several cytotoxic agents, including taxanes,
gemcitabine, vinorelbine and irinotecan, have been investigated
for second-line treatment, as either single agent or combination
(Table 3). Out of the many Phase II trials, with a relatively small
number of patients and uneven distribution of sensitive vs
refractory disease, some agents, such as paclitaxel, irinotecan
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theless, the lack of comparative trials prevents any formal
conclusions.
Pemetrexed (Table 4), recently tested in three Phase II studies,
has shown minimal activity in relapsed SCLC patients. High-dose
pemetrexed can be given without significant increase in serious
toxicities, but this does not seem to increase efficacy (Hanna et al,
2006b; Gronberg et al, 2008; Socinski et al, 2008).
New agents and ongoing research
As well as in first-line chemotherapy, amrubicin have shown
impressive results for the second-line treatment of relapsed SCLC.
High response rates (between 37% and 60%) have been reported
for single-agent amrubicin in three Phase II Japanese studies
conducted in a population with sensitive and resistant relapses
(Kato et al, 2006; Kudoh et al, 2006; Onoda et al, 2006). The overall
Table 2 Randomised trials for the treatment of relapsed SCLC
Results
Response rate (%)
Authors Study type Regimen Schedule Patients (n) ORR CR PR SD
Median TTP
(weeks)
Median survival
(weeks)
von Pawel et al
(1999)
Randomised
Phase II
CAV vs topotecan Cyclophosphamide 1000mgm
–2+
doxorubicin 45mgm
–2+ vincristine
2mgm
–2, day 1, q3w
104 18.3 1 18 12 — 24.7
IV topotecan: 1.5mgm
–2, days 1–5, q3w 107 24.3 0 26 21 — 25.0
von Pawel et al
(2001)
Randomised
Phase II
Oral topotecan vs IV
topotecan
Oral topotecan: 2.3mgm
–2, days 1–5, q3w 52 23 2 21 19 14.9 32
IV topotecan: 1.5mgm
–2, days 1–5, q3w 54 15 4 11 30 13.1 25
Eckardt (2007) Randomised
Phase III
Oral topotecan vs IV
topotecan
Oral topotecan: 2.3mgm
–2, days 1–5, q3w 153 18 — — 18 — 33
IV topotecan: 1.5mgm
–2
, days 1–5, q3w 151 22 — — 23 — 35
O’Brien et al
(2006)
Randomised
Phase III
Oral topotecan
+ BSC vs BSC alone
Oral topotecan: 2.3mgm
–2, days 1–5, q3w 71 7 0 7 44 16.3 25.9
BSC alone 70 — — — — — 13.9
Abbreviations: ORR¼overall response rate; CR¼complete response; PR¼partial response; SD¼stable disease; TTP¼time to progression; CAV¼cyclophosphamide,
doxorubicin and vincristine; BSC¼best supportive care; SCLC¼small cell ling cancer.
Table 3 Clinical studies of targeted agents for the treatment of SCLC
Result
Authors
Targeted
agent
Combination
regimen
Targeted
population Phase
Sample
size RR OS/PFS (months) Conclusion
TKs inhibitors
Dy et al (2005) Imatinib — Relapsed, resistant/
sensitive [c-Kit +]
II 29 No PR
No SD
OS: R¼3.9
S¼5.3
No clinical activity
Krug et al (2005) — Relapsed, resistant/
sensitive [c-Kit +]
II 12 No PR
No SD
OS: 2 No clinical activity
Johnson et al (2003) — ES, untreated relapsed,
sensitive
II 19 No PR — No clinical activity
Schneider et al (2006) — ES, if no PD after I-line
IP 4 [c-Kit +]
II 14 No PR OS: 10 Disease stability not
maintained
Spigel et al (2007) Carboplatin/irinotecan ES, untreated II 69 PR 66% OS: 8.4 No improvement in results
from chemotherapy alone
Moore et al (2006) Gefitinib — Relapsed, resistant/
sensitive
II 19 No PR 10% SD OS: 206 days No clinical activity
Anti-angiogenic agents
Sandler et al (2007) Bevacizumab Cisplatin/etoposide ES, untreated II 64 OR 69% PFS at 6 months: 33% Promising results
Ready et al (2007) Irinotecan/cisplatin ES, untreated II 72 CR 3%
PR 71%
OS: 11.7 Primary end point not
reached
Jalal et al (2008) Paclitaxel Relapsed, sensitive II 34 PR 11%
SD 55%
OS: 21 weeks Active regimen
Pujol et al (2007) Thalidomide PCDE ES, after response to
PCDE 2
III 119 — OS: 11.7/8.7 (NS) Thalidomide did not
improve survival
Lee et al (2008) Carboplatin/etoposide ES and LS, untreated III 724 — OS: 10.2/10.5 (NS) Thalidomide did not
improve survival
Gitlitz et al (2008) Sorafenib — Relapsed (platinum-
treated)
II 81 PR 4%
SD 32%
 7, S
 5, R
Clinical activity
Ramalingam et al (2008) Cediranib
(ZD2171)
— Relapsed (platinum-
treated)
II 25 PR: 1 patient
SD: 9 patients
PFS 1.2 No clinical activity
Arnold et al (2007) Vandetanib
(ZD6474)
— ES and LS, untreated.
If no PD after first-line
platinum-based (and
PCI/TRT)
II 107 — PFS and OS NS No efficacy as maintenance
therapy
Abbreviations: RR¼response rate; PR¼partial response; SD¼stable disease; OS¼overall survival; PD¼progressive disease; ES¼early-stage; PFS¼progression-free survival;
CR¼complete response; PCDE¼etoposide plus cisplatin and cyclophosphamide plus 40-epidoxorubicin; LS¼late stage; S¼sensitive; R¼resistant; NS¼not significant;
PCI¼prophylactic cranial irradiation; TRT¼thoracic radiotherapy; OR¼overall response.
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resistant patients, respectively (Kato et al, 2006; Onoda et al, 2006).
Interestingly, the response rate and the median survival time were
similar in both sensitive and resistant patients (Table 4). A US
Phase II trial has investigated single-agent amrubicin in patients
with refractory or resistant SCLC (Ettinger et al, 2008). Activity
was observed and the most frequent toxicity was myelosuppres-
sion, but no classic anthracycline-induced cardiotoxicity has been
observed.
A randomised Phase II trial has compared amrubicin and
topotecan in earlier treated SCLC. This study further supports the
efficacy of amrubicin in both sensitive (overall response rate of
53%) and resistant patients (overall response rate of 17%). A
higher response rate was achieved with amrubicin compared with
topotecan (Inoue et al, 2008). This Japanese study unfortunately
used topotecan at a dose of 1mgm
–2 rather than the current
recommended dose of 1.5mgm
–2. Preliminary results of a second
Phase II trial seem to confirm a trend in favour of amrubicin over
topotecan as single-agent chemotherapy for sensitive relapsed
SCLC in terms of response rate, but PFS was not statistically
different. Further evaluations are currently ongoing within a Phase
III setting.
At present, a second drug is under investigation in a Phase III
setting. Picoplatin is a platinum analogue with some activity in
relapsed SCLC, as shown in an earlier Phase II trial conducted in
refractory, resistant and sensitive patients (Eckardt et al, 2009).
The Phase III study evaluates picoplatin plus best supportive care
vs best supportive care alone in both refractory and relapsed
patients (SPEAR trial).
Targeted therapy is currently being explored in relapsed SCLC.
Some of the first agents investigated as second-line therapy were
imatinib and gefitinib; however, both agents were unsuccessful
(Table 3). Current research is now focused on angiogenesis
inhibitors (Table 3).
From preliminary results of a Phase II trial, bevacizumab in
combination with paclitaxel in chemosensitive relapsed SCLC
seems to be an active regimen (Jalal et al, 2008). Cediranib, a
highly potent inhibitor of VEGFR-1, -2 and -3, has also shown
limited anti-cancer activity as monotherapy in chemosensitive
relapsed patients (Ramalingam et al, 2008).
Sorafenib and sunitinib are multikinase inhibitors acting on
pathways involved in tumour progression and angiogenesis, and
are both undergoing investigation for the treatment of SCLC in
either the first- or second-line setting. The only data available so
far are on sorafenib, which seems to be a promising agent with a
median survival of 7 and 5 months in platinum-sensitive and
platinum-refractory patients, respectively (Gitlitz et al, 2008). This
compared favourably with historical controls receiving salvage
chemotherapy. A Phase I trial of weekly topotecan in combination
with sorafenib in treatment of relapsed SCLC has been
commenced.
NKH-1 (or CD56) is a neural adhesion molecule that is highly
expressed in SCLC (Fischer and Arcaro, 2008). The immunotoxin
N901-bR is a murine monoclonal antibody directed against CD56.
Hu 901-DM1 is an immunoconjugate created by the conjugation of
the maytansinoid drug DM 1 to a humanised version of the murine
monoclonal antibody N901. At a dose of 60mgm
–2per week, 2 out
of 10 patients with relapsed SCLC obtained a partial response and
another one a minor response; this study is ongoing (Fossella et al,
2005).
Proteosome inhibitors
Bortezomib targets the ubiquitin–proteosome pathway
interfering with p21, p27, p53, cyclins D, E and A, nuclear
factor kB and members of the Bax family. In a Phase II trial
using bortezomib at a dose of 1.3mgm
–2 on Days 1, 4, 8 and
11 every 21 days, only one partial response was obtained. Further
studies are, therefore, underway to assess the benefit of combining
bortezomib with topotecan in the second-line setting (Johl et al,
2005).
Table 4 Evaluated drugs in relapsed SCLC
Results
Drug Dose/schedule Authors Population Phase Patients (n) Response (%) OS Conclusion
Gemcitabine 1250mgm
–2days 1, 8; q3w Hoang et al (2003) Se, Rs, Re II 27 No response 6.4 months Limited activity
1000mgm
–2days 1, 8, 15; q4w van der Lee et al (2001) Rs, Re (76% 41
earlier line)
II 41 13% 17 weeks Modest activity
1000mgm
–2days 1, 8, 15 q4w Masters et al (2003) Se, Rs, Re II 46 11.9% 7.1 months Modest activity
Irinotecan 100mgm
–2weekly Masuda et al (1992) Se, Rs, Re II 16 47% 6.8 months Active agent
Paclitaxel 175mgm
–2; q3w Smit et al (1998) Rs II 24 29% 100 days Active agent
200mgm
–2; q3w Joos et al (2004) Rs, Re II 44 20% 4 months Active agent
Vinorelbine 25mgm
–2weekly Furuse et al (1996) Se, Rs, Re II 24 12.5% — Modest activity
30mgm
–2weekly Jassem et al (1993) Se II 26 16% — Modest activity
Pemetrexed 500mgm
–2; q3w Hanna et al (2006b) Se, Rs II 43 Se: 1 PR
Rs: 1 PR
— Minimal activity
900mgm
–2; q3w Gronberg et al (2008) Se, Rs II 34 Se: 4.5%
Rs: 2.9%
17.6 weeks Limited activity
900mgm
–2; q3w Socinski et al (2008) Se, Rs II 121 0.9% (1 PR in Se) 2.5–6.1 months Minimal activity
Amrubicin 40mgm
–2days 1–3; q3w Onoda et al (2006) Se, Rs II 60 Se OR: 52%
Rs OR: 50%
Se: 11.6 months
Rs: 10.3 months
Significant activity
45mgm
–2days 1–3; q3w Kato et al (2006) Se, Rs II 35 Se OR: 50%
Rs OR: 60%
8.8 months Significant activity
40mgm
–2days 1–3; q3w Kudoh et al (2006) Se, Rs II 19 OR: 37% — Active agent
40mgm
–2days 1–3; q3w Ettinger et al (2008) Rs, Re II 63 PR: 13/39 — Active agent
Amrubicin: 40mgm
–2days 1–3;
q3w
Topotecan: 1mgm
–2days 1–5
Inoue et al (2008) Se, Rs II 60 38% vs 13% — Amrubicin may be
superior to topotecan
Picoplatin 150mgm
–2; q3w Bentzion et al (2007) Se, Rs, Re II 77 — 28.1 weeks Compares favourably with
other therapeutic options
Abbreviations: OS¼overall survival; Se¼sensitive (initially responded and then relapsed/progressed between 60 and 180 days); Rs¼resistant (initially responded to first-line
platinum-containing chemotherapy and then relapsed/progressed within 60–90 days); Re¼refractory (failed or progressed with first-line platinum-containing chemotherapy);
PR¼partial response; OR¼overall response.
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The SCLC is a significant healthcare problem worldwide because of
its aggressive nature and high propensity for relapse. Combination
chemotherapy continues to be the mainstay of SCLC treatment in
the first-line setting; the combination of cisplatin or carboplatin
with etoposide is the most commonly used regimen. Despite
relatively high initial response rates, most patients with
SCLC eventually relapse, but treatment options for patients with
relapsed SCLC are limited. Topotecan is currently the only
approved single-agent for second-line therapy and recent data
with oral topotecan show that more of these patients than
suggested earlier can achieve further responses, symptom control
and survival prolongation.
A number of other chemotherapeutic agents, including irinote-
can, paclitaxel and amrubicin, have shown some activity in small
Phase II/III trials when used as monotherapy or in combination
with other cytotoxic agents. Recent progress in the understanding
of the biology of SCLC has led to the identification of crucial
signalling pathways and the subsequent development of targeted
therapies. Several novel molecules are presently undergoing
evaluation, and represent potential future additions to the
treatment repertoire for SCLC.
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